Di-san junyi daxue xuebao (Sep 2020)

Prognostic value of 18F-FDG PET/CT SUVmax before R-CHOP treatment for diffuse large B cell lymphoma: an analysis of 76 cases

  • LEI Chengming,
  • WANG Lidan,
  • LI Wenbo,
  • HUANG Ying,
  • DENG Xi

DOI
https://doi.org/10.16016/j.1000-5404.202004326
Journal volume & issue
Vol. 42, no. 17
pp. 1693 – 1698

Abstract

Read online

Objective ;To investigate the survival predictive value of the maximum standard uptake value (SUVmax) of 18F-fluorodeoxy glucose (18F-FDG) in positron emission tomography/computed tomography (PET/CT) in diffuse large B cell lymphoma (DLBCL) patients before R-CHOP treatment. Methods ;The clinical data of 76 DLBCL patients who underwent PET/CT examination before R-CHOP treatment in our hospital from 2015 to 2019 were collected. The age, gender, 18F-FDG SUVmax value of PET/CT imaging, immunological markers and immune types of these DLBCL were analyzed using R-Studio software for prognosis by univariate and multivariate analyses. According to the 18F-FDG SUVmax value, the 76 patients were divided into the SUVmax≤10 group and the SUVmax > 10 group. Chi-square test was used to compare the differences in the age, gender, clinical stage, B symptoms, LDH level, and international prognostic index (IPI) between the 2 groups. Results Both the univariate or multivariate analyses showed that age, 18F-FDG SUVmax and IPI score were all prognostic factors for prognosis in DLBCL patients, The relative risk (RR) was 12.56 for those >60 years old/≤60 years old (95%CI: 3.32~47.54), 3.11 for SUVmax >10/SUVmax ≤10 (95%CI: 1.04~9.34), and 5.67 for IPI score >2/≤2 (95%CI: 1.09~29.60). No statistical relationship were found in the expression of immunological markers, CD10, BCL-6 and MUM-1 with the prognosis (P>0.05). There were no significant differences in age, clinical stage and other clinical indicators between the SUVmax≤10 group and the SUVmax>10 group (P>0.05). Conclusion ;The SUVmax value of 18F-FDG PET/CT imaging before treatment is of certain significance in the survival prediction for DLBCL patients after R-CHOP chemotherapy

Keywords